Santen Pharmaceutical Co., Ltd.
GPTKB entity
Properties (50)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:Company
|
gptkbp:acquisition |
gptkb:Ophthotech_Corporation
Santen_acquired_100%_of_the_shares_of_Eyevance_Pharmaceuticals Santen_acquired_100%_of_the_shares_of_Oculis_SA |
gptkbp:awards |
received multiple awards for innovation
recognized for excellence in ophthalmology |
gptkbp:CEO |
Akihiro_Santen
|
gptkbp:clinicalTrials |
ongoing clinical trials for new ophthalmic drugs
|
gptkbp:collaborations |
collaborates with universities for research
|
gptkbp:communityEngagement |
engages in community health programs
supports eye health awareness campaigns |
gptkbp:financialPerformance |
increased investment in R&D
reported steady growth in revenue |
gptkbp:focus |
research and development
|
gptkbp:founded |
1890
|
gptkbp:globalPresence |
operates in over 30 countries
|
gptkbp:headquarters |
gptkb:Osaka,_Japan
|
https://www.w3.org/2000/01/rdf-schema#label |
Santen Pharmaceutical Co., Ltd.
|
gptkbp:industry |
pharmaceuticals
|
gptkbp:market |
gptkb:North_America
gptkb:Asia-Pacific Europe |
gptkbp:numberOfEmployees |
approximately 2,000
|
gptkbp:operatesIn |
gptkb:Asia
gptkb:Japan gptkb:North_America Europe |
gptkbp:partnerships |
gptkb:Aerie_Pharmaceuticals
gptkb:Bausch_+_Lomb Novartis |
gptkbp:patentCitation |
developed proprietary drug delivery systems
holds numerous patents in ophthalmic formulations |
gptkbp:products |
contact lens solutions
surgical products dry eye treatments anti-glaucoma medications ophthalmic_pharmaceuticals |
gptkbp:researchFocus |
retinal diseases
ocular diseases corneal diseases inflammatory eye diseases |
gptkbp:revenue |
approximately 200 billion JPY
|
gptkbp:specializesIn |
ophthalmology
|
gptkbp:subsidiary |
gptkb:Santen_GmbH
gptkb:Santen_Inc. gptkb:Santen_SA |
gptkbp:sustainabilityInitiatives |
environmental sustainability programs
corporate social responsibility initiatives |
gptkbp:vision |
to be a global leader in ophthalmology
|
gptkbp:website |
www.santen.com
|